This EASL Studio episode brings key insights from the 2025 EASL–AASLD Consensus Conference on Primary Biliary Cholangitis (PBC).

Experts explore the use of surrogate endpoints, the challenges in current trial design and regulation, the value of real-world evidence, and how quality-of-life assessment can support future pathways.

This EASL Studio is supported by Advanz Pharma, Gilead Sciences Europe Ltd, GSK, Intercept, IPSEN and Mirum. EASL has received no input from Advanz Pharma, Gilead Sciences Europe Ltd, GSK, Intercept, IPSEN or Mirum with regards to the content of this programme.

Moderator: David Jones

Speakers: Marco Carbone, Bettina Hansen, and Ana Lleo